Takara Bio Overview
- Year Founded
-
2002
- Status
-
Public
- Employees
-
1,779
- Stock Symbol
-
4974
- Investments
-
8
- Share Price
-
$5.39
- (As of Friday Closing)
Takara Bio General Information
Description
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
Contact Information
Website
www.takara-bio.co.jpCorporate Office
- Nojihigashi 7-4-38
- Kusatsu, Shiga 525-0058
- Japan
Corporate Office
- Nojihigashi 7-4-38
- Kusatsu, Shiga 525-0058
- Japan
Takara Bio Stock Performance
As of 20-Jun-2025, Takara Bio’s stock price is $5.39. Its current market cap is $649M with 120M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.39 | $5.35 | $4.89 - $7.74 | $649M | 120M | 224K | $0.06 |
Takara Bio Financials Summary
As of 31-Mar-2025, Takara Bio has a trailing 12-month revenue of $295M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 |
|---|---|---|---|---|
| EV | 485,444 | 485,444 | 526,547 | 1,331,820 |
| Revenue | 295,365 | 295,365 | 301,094 | 577,197 |
| EBITDA | 40,646 | 40,646 | 53,367 | 190,875 |
| Net Income | 6,827 | 6,827 | 10,243 | 118,273 |
| Total Assets | 837,557 | 837,557 | 801,136 | 969,648 |
| Total Debt | 7,358 | 7,358 | 6,396 | 7,295 |
Takara Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Takara Bio Comparisons
Industry
Financing
Details
Takara Bio Competitors (61)
One of Takara Bio’s 61 competitors is Lonza Group, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lonza Group | Corporation | Basel, Switzerland | ||||
| Advanced Cell Diagnostics | Formerly VC-backed | Minneapolis, MN | ||||
| J. Craig Venter Institute | Corporate Backed or Acquired | La Jolla, CA | ||||
| 10x Genomics | Formerly VC-backed | Pleasanton, CA | ||||
| BioLegend | Formerly Accelerator/Incubator backed | San Diego, CA |
Takara Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Takara Bio Patents
Takara Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024049175-A | Method for detecting accurately two bases continuous replacement in variant sars-cov-2 | Pending | 28-Sep-2022 | ||
| EP-4502162-A1 | Selective regulatory gene (srg) system for genetically modified immune cell therapy | Pending | 29-Mar-2022 | ||
| US-20250179147-A1 | Selective regulatory gene (srg) system for genetically modified immune cell therapy | Pending | 29-Mar-2022 | ||
| EP-4502166-A1 | Efficient system for producing adeno-associated virus (aav) vector | Pending | 25-Mar-2022 | ||
| US-20250197887-A1 | Efficient system for producing adeno-associated virus (aav) vector | Pending | 25-Mar-2022 | C12N15/86 |
Takara Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Takara Bio Investments & Acquisitions (8)
Takara Bio’s most recent deal was a Merger/Acquisition with ViSpot. The deal was made on 27-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ViSpot | 27-Jan-2025 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| StemCells (Stem Cell-related Research Products) | 11-Nov-2014 | Corporate Asset Purchase | Buildings and Property | ||
| Cellectis bioresearch (Sweden) | 04-Sep-2014 | Merger/Acquisition | Biotechnology | ||
| Nanosphere | 26-Apr-2006 | Later Stage VC | Diagnostic Equipment | ||
| Takara Bio USA | 01-Aug-2005 | Merger/Acquisition | Discovery Tools (Healthcare) |
Takara Bio ESG
Risk Overview
Risk Rating
Updated May, 27, 2025
28.01 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile
Pharmaceuticals
Industry
of 844
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Takara Bio Exits (4)
Takara Bio’s most recent exit was on 26-Apr-2006 from Nanosphere. The exit was categorized as with 4 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Nanosphere | 26-Apr-2006 | Completed |
|
||
| Helixmith | 23-Feb-2005 | Completed |
|
||
| Nanosphere | 26-Nov-2002 | Completed |
|
||
| Helixmith | 01-Mar-2000 | Corporate | Completed |
Takara Bio FAQs
-
When was Takara Bio founded?
Takara Bio was founded in 2002.
-
Where is Takara Bio headquartered?
Takara Bio is headquartered in Kusatsu, Japan.
-
What is the size of Takara Bio?
Takara Bio has 1,779 total employees.
-
What industry is Takara Bio in?
Takara Bio’s primary industry is Biotechnology.
-
Is Takara Bio a private or public company?
Takara Bio is a Public company.
-
What is Takara Bio’s stock symbol?
The ticker symbol for Takara Bio is 4974.
-
What is the current stock price of Takara Bio?
As of 20-Jun-2025 the stock price of Takara Bio is $5.39.
-
What is the current market cap of Takara Bio?
The current market capitalization of Takara Bio is $649M.
-
What is Takara Bio’s current revenue?
The trailing twelve month revenue for Takara Bio is $295M.
-
Who are Takara Bio’s competitors?
Lonza Group, Advanced Cell Diagnostics, J. Craig Venter Institute, 10x Genomics, and BioLegend are some of the 61 competitors of Takara Bio.
-
What is Takara Bio’s annual earnings per share (EPS)?
Takara Bio’s EPS for 12 months was $0.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
